El valor de la selección de pacientes en NSCLC: tratamiento de segunda línea en pacientes PD-L1 positivo - page 28

OVERALL SURVIVAL, ITT (N = 850)

Barlesi et al, Atezolizumab Phase III OAK Study.

http://tago.ca/9Hh

Stratified HR.

Atezolizumab

Docetaxel

Median 9.6 mo

(95% CI, 8.6, 11.2)

Median 13.8 mo

(95% CI, 11.8, 15.7)

Overall Survival (%)

Months

HR, 0.73

(95% CI, 0.62, 0.87)

= 0.0003

Minimum follow up = 19 months

OAK STUDY

INDICACIÓN PENDIENTE DE APROBACIÓN,

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,18,19,20,21,22,23,24,25,26,27 29,30,31,32,33,34,35,36,37,38,...43